Top 15 Chinese IVD Companies by Revenue in 2022

Zhiyan Consulting Data Center released the net profit ranking of Chinese medical device listed companies in the first quarter of 2022, ranking 109 Chinese listed medical companies according to their net profit in the first quarter of 2022.

Andon Health Co., Ltd.

In 2021, Andon Health earn more than 900 million CNY, a year-on-year increase of 274.96%. The fourth quarter made a big profit of 859 million yuan, accounting for 94.50%, and the iHealth series products made a significant contribution to the increase in performance.

During the reporting period, Andon Health’s revenue was 21.737 billion CNY, a year-on-year increase of 6646.79%. The net profit exceeded 10 billion yuan, reaching 14.312 billion yuan, a year-on-year increase of 37527.35%.

Based on this estimate, the net profit of Andon Health in the first quarter of this year is almost 15 times that of the whole of last year.

Assure Tech (Hangzhou) Co.,Ltd.

In just over half a year since its listing, it earned nearly 2.7 billion CNY in the first quarter of this year, with a year-on-year increase of 3,147% in net profit. It made nearly 2.7 billion CNY in the first quarter of this year, and its net profit increased by 3,147% year-on-year. In the first three months of 2022 , Assure Tech earned more than three times the amount of money last year.

Assure Tech's COVID product is an antigen self-testing agent, which obtained the Canadian IO certification in February 2021 and the EU CE certification in November. In addition, according to Assure Tech, the company's products are mainly sold in Canada, Australia, the European Union and other regions, with an average sales price of 1-2 US dollars.

In the purchase list of Canada's COVID rapid test kits announced on March 17 this year, the Canadian company BTNX received 317 million orders, and Assure Tech received 7,837,600 orders. BTNX is the main ODM customer of Assure Tech, which means, more than half of the more than 600 million test kits purchased by the Canadian government in this period were directly or indirectly produced by Assure Tech.

Shenzhen Mindray Bio-Medical Electronics Co.,Ltd

In 2021, Mindray will achieve an operating income of 25.270 billion CNY, a year-on-year increase of 20.18%; a net profit attributable to the parent of 8.002 billion CNY, a year-on-year increase of 20.19%. With a market value of over 300 billion and an annual revenue of over 25 billion CNY, Mindray ranks first in the medical device field. Since its listing in 2018, Mindray has maintained a double increase in annual revenue and net profit of more than 20% for four consecutive years, which is indeed a difficult task for a device company.

After experiencing the impact of the epidemic, Mindray has made great progress in breakthroughs overseas, especially in the high-end market. The epidemic in 2020 triggered emergency procurement, which pushed Mindray to complete the breakthrough of more than 700 blank high-end customers in the international market. In 2021, we will continue to achieve breakthroughs in over 700 blank high-end customers.

Zhejiang Orient Gene Biotech Co.,Ltd.

In 2021, the company's operating income was 10.169 billion CNY, a year-on-year increase of 211.43%, the net profit was 4.920 billion CNY, a year-on-year increase of 193.33%, and the basic earnings per share will be 41.00 CNY.

From the perspective of business structure, "POCT point-of-care diagnostic reagents" are the main source of the company's operating income. Specifically, the operating income of "POCT instant diagnostic reagents" was 10.15 billion CNY, accounting for 100% of the revenue, and the gross profit margin was 74.1%.

According to the 2022 first quarter report of Orient Gene Biotech, the company's main income was 4.746 billion CNY, up 112.28% year-on-year; net profit attributable to the parent was 2.067 billion CNY, up 74.2% year-on-year; non-net profit deducted was 2.084 billion CNY, up 75.99% year-on-year;

Daan Gene Co.,ltd.

In comparison, from 2016 to 2019, Daan Gene achieved revenue of 1.613 billion CNY, 1.542 billion CNY, 1.479 billion CNY and 1.098 billion CNY respectively, and the net profit attributable to the parent in the same period was 107 million CNY, 86 million CNY, 102 million CNY, and 92 million CNY respectively.

In 2020, the company achieved revenue of 5.341 billion CNY, a year-on-year increase of 386.35%, and net profit of 2.449 billion CNY, a year-on-year increase of 2556.80%. In 2021, corporate revenue and net profit attributable to the parent company will continue to grow by more than 40%, reaching 7.664 billion CNY and 3.618 billion CNY respectively.

Among the contribution to performance growth, nucleic acid detection products are the most. In 2021, Daan Gene 2019-nCoV nucleic acid detection kit (fluorescent PCR method) achieved revenue of 4.894 billion CNY, a year-on-year increase of 64.48%, and a gross profit margin of 88.65%.

Wuhan Easy Diagnosis Biomedicine Co.,ltd.

Before the epidemic, Wuhan Easy Diagnosis Biomedicine was mainly engaged in the research and development, production and sales of POCT rapid diagnostic products, and rapid diagnostic reagents accounted for nearly 90% of Wuhan Easy Diagnosis Biomedicine’s revenue.

In March 2020, company’s COVID nucleic acid reagent was listed through the national emergency approval channel. According to Wuhan Easy Diagnosis Biomedicine, in 2021, the sales revenue of COVID nucleic acid detection reagents will account for about 71.46% of the company's revenue, and the gross profit margin will be 86.88%. At present, in China Xinjiang, Guangdong, Zhejiang, Heilongjiang, Hubei and other provinces has a high proportion.

In 2021, Wuhan Easy Diagnosis Biomedicine will achieve revenue of about 2.83 billion CNY, a year-on-year increase of 195.05%, and a net profit of about 1.413 billion CNY, a year-on-year increase of 201.37%. In the first quarter of 2022, the company's performance continued to grow, with revenue reaching 2.487 billion CNY, a year-on-year increase of 267.41%; net profit attributable to the parent was 1.389 billion CNY, a year-on-year increase of 307.05%.

Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd

During the reporting period, Wantai Bio achieved operating income of 3.171 billion CNY, a year-on-year increase of 284.85%; net profit attributable to the parent was 1.331 billion CNY, a year-on-year increase of 360.18%.

The growth in performance mainly came from bivalent cervical cancer vaccines, reagents, and active raw materials. Among them, the revenue of bivalent HPV vaccine increased by nearly 2 billion CNY, and the revenue of reagents and active raw materials increased by about 350 million CNY. The growth of active raw materials is mainly also the growth of COVID related raw materials.

Hangzhou Alltest Biotech Co.,Ltd.

In the first quarter of 2022, Alltest Biotech achieved operating income of 2.099 billion CNY, a year-on-year increase of 628.17%; net profit attributable to the parent was 104,900 CNY, a year-on-year increase of 598.18%. This was mainly due to the substantial increase in revenue from COVID-19 antigen testing products compared to the same period last year.

In the past two years, the performance of Alltest Biotech has increased significantly, mainly relying on the COVID reagent. In 2021, the operating income will be 1.873 billion CNY, a year-on-year increase of 64.98%. Among them, the revenue of new crown detection products was 1.603 billion CNY, accounting for 85.52% of the revenue.

Guangzhou Wondfo Biotech Co.,Ltd.

As one of the leading POCT companies in China, in 2021, the sales revenue of Wanfu Bio’s four product lines of regular business will be about 1.916 billion CNY, a year-on-year increase of 38.18%.

In the first quarter of this year, the revenue of Guangzhou Wondfo Biotech Co.,Ltd. has exceeded that of the whole year of last year.

According to the quarterly report, Wanfu Bio achieved revenue of 2.625 billion CNY in the first quarter of 2022, a year-on-year increase of 276.87%; net profit was 904 million CNY, a year-on-year increase of 481.32%.

Sansure Biotech Inc.

In the first quarter of this year, Sansure Biotech seems to have reversed the decline in both revenue and net profit last year, achieving revenue of 1.44 billion CNY, a year-on-year increase of 23.81%; net profit of 652 million CNY, a year-on-year increase of 4.78%.

Jiangsu Bioperfectus Technologies Co.,ltd.

According to the first quarter report of 2022, the operating income of Jiangsu Bioperfectus Technologies was 1.522 billion CNY during the reporting period, a year-on-year increase of 77.69%; the net profit attributable to shareholders of the listed company was 631 million CNY, a year-on-year increase of 62.9%.

Beijing Hotgen Biotech Co.,ltd.

From January 1, 2022 to March 31, 2022, Rejing Bio achieved operating income of 1.364 billion CNY, a year-on-year increase of 11.14%, net profit of 606 million yuan, a year-on-year increase of 0.77%, and basic earnings per share of 9.74 CNY.

During the reporting period of the first quarter, the total assets at the end of the period were 3.922 billion CNY, the operating profit was 734 million CNY, the accounts receivable was 114 million CNY, and the net cash flow from operating activities was 59.689 million CNY. The cash received was 1.053 billion CNY.

Lepu Medical Technology(Beijing)Co.,Ltd.

According to the 2022 first quarter report of  Lepu Medical Technology, the company's main income was 2.549 billion CNY, a year-on-year decrease of 7.28%; the net profit attributable to the parent was 545 million CNY, a year-on-year decrease of 24.89%; the deducted non-net profit was 547 million CNY, a year-on-year decrease of 19.83%.

Shenzhen YHLO Biotech Co.,Ltd.

According to YHLO Biotech’s 2022 first quarter report, the main revenue was 1.37 billion CNY, up 481.55% year-on-year; the net profit attributable to the parent was 511 million CNY, up 1257.79% year-on-year; the deducted non-net profit was 510 million CNY, up 1366.26% year-on-year.

Guangdong Hybribio Biotech Co.,Ltd.

The 2022 first quarter report of Kaipu Bio showed that the company's main income was 1.511 billion CNY, up 147.87% year-on-year; the net profit attributable to the parent was 500 million CNY, up 190.64% year-on-year; the deducted non-net profit was 492 million CNY, up 201.55% year-on-year.